Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
May 5, 2026 4:01 PM EDTTotal First-Quarter 2026 Net Product Sales of $811.0 Million,
An Increase of 44% Year-Over-Year
Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKATTM XR (diazoxide
choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026
Initiated Phase 2 Clinical Study of NBI-1117570, a Dual M1 / M4 Selective Agonist, in Adults with
Schizophrenia
Reaffirmed 2026 Full-Year INGREZZA® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion
SAN DIEGO, May 5,... More
